Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 1.00 |
| ▸ | CSNK1D | P48730 | 2/20 | 1.00 |
| ▸ | CSNK1E | P49674 | 2/20 | 1.00 |
| ▸ | ACVR1B | P36896 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | TGFBR2 | P37173 | 1/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 1.00 |
| ▸ | CSNK1A1L | Q8N752 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-431542 SCHEMBL29359059 | 1.00 | TGFBR1 (1.00) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL29381798 | 1.00 | TGFBR1 (1.00) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL29432843 | 0.99 | TGFBR1 (0.98) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL2681356 | 0.99 | TGFBR1 (0.98) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| SCHEMBL29362480 | 0.94 | TGFBR1 (1.00) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| SCHEMBL373737 | 0.94 | TGFBR1 (1.00) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL155156 | 0.92 | TGFBR1 (0.85) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL29353092 | 0.92 | TGFBR1 (0.85) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL30033986 | 0.92 | TGFBR1 (0.85) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B | |
| Sb-431542 SCHEMBL21046666 | 0.91 | TGFBR1 (0.84) | TGFBR1CSNK1A1CSNK1DCSNK1EACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692329-A1 | COMPOSITION FOR INDUCING DIRECT DIFFERENTIATION OF STEM CELLS INTO CORNEAL ENDOTHELIAL CELLS AND METHOD FOR INDUCING DIRECT DIFFERENTIATION USING SAME | The Asan Foundation (KR) | 2026-02-11 | — | — | EP | claimed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| EP-4079314-B1 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4070803-B1 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-10-08 | — | — | EP | claimed |
| US-12428623-B2 | Generation of midbrain-specific organoids from human pluripotent stem cells | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-09-30 | — | — | US | claimed |
| US-20250241964-A1 | SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2025-07-31 | — | — | US | claimed |
| US-20250188420-A1 | MATURING AGENT HAVING BOTH OF ALK5 INHIBITORY ACTIVITY AND CDK8/19 INHIBITORY ACTIVITY | Orizuru Therapeutics, Inc. (JP) | 2025-06-12 | — | — | US | claimed |
| EP-3430132-B1 | GENERATION OF MIDBRAIN-SPECIFIC ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY SCIENCE TECH & RES (SG) | 2025-04-30 | — | — | EP | claimed |
| EP-4516894-A1 | MATURING AGENT HAVING BOTH OF ALK5 INHIBITORY ACTIVITY AND CDK8/19 INHIBITORY ACTIVITY | Orizuru Therapeutics, Inc. (JP) | 2025-03-05 | — | — | EP | claimed |
| US-RE50313-E1 | Musculoskeletal stem cell and medium for inducing differentiation of musculoskeletal stem cell | CELLATOZ THERAPEUTICS, INC. (KR) | 2025-02-25 | — | — | US | claimed |
| EP-1771171-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | Schering-Plough Ltd. (CH) | 2007-04-11 | — | — | EP | claimed |
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | SCHERING CORPORATION | 2006-08-31 | — | — | US | claimed |
| US-20060183778-A1 | Osteogenesis-promotion enhancer and method of screening the same | JAPANESE FOUNDATION OF CANCER RESEARCH (JP) | 2006-08-17 | — | — | US | claimed |
| WO-2006025988-A1 | USE OF ALK 5 INHIBITORS TO MODULATE OR INHIBIT MYOSTATIN ACTIVITY LEADING TO INCREASED LEAN TISSUE ACCRETION IN ANIMALS | SCHERING-PLOUGH LTD. (CH) | 2006-03-09 | — | — | WO | claimed |
| EP-1632249-A1 | OSTEOGENESIS-PROMOTION ENHANCER AND METHOD OF SCREENING THE SAME | Nippon Shinyaku Co., Ltd. (JP) | 2006-03-08 | — | — | EP | claimed |
| EP-1169317-B1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 2003-01-15 | — | — | EP | claimed |
| JP-2002541253-A | — | — | 2002-12-03 | — | — | JP | claimed |
| US-6465493-B1 | SUCH AS 4-(4-(4-FLUOROPHENYL)-5-(2-PYRIDYL)-1-HYDROXY-1H-IMIDAZOL-2-YL)BENZONITRILE; ALK5 MEDIATED DISEASES SUCH AS ARTHRITIS, OSTEOPOROSIS, KIDNEY AND RENAL DISEASES, CONGES-TIVE HEART FAILURE, ULCERS, DIABETIC NEPHROPATHY | SMITHKLINE BEECHAM CORPORATION | 2002-10-15 | — | — | US | claimed |
| EP-1169317-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-09 | — | — | EP | claimed |
| WO-2000061576-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194845-A1 | Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals | ALK, ACVR1, MSTN | TGFBR1 56/4885CSNK1A1 3576/4885CSNK1D 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.